Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

All News

Product Approvals and Launches

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

Partners

Polls and Quizzes

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

BIOSIMILAR APPROVALS

Cameron Santoro is an associate editor for The Center for Biosimilars

Videos

Here are the top 5 biosimilar articles for the week of November 18, 2024. 

The Top 5 Biosimilar Articles for the Week of November 18

This webinar celebrating Global Biosimilars Week was hosted by The Center for Biosimilars® in partnership with the International Generics and Biosimilars Association.

Webinar: Streamlining the Regulatory Process to Advance Access to Biosimilars

Articles

Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.

Boosting Health Care Sustainability: The Role of Biosimilars in Latin America

Although financial incentives introduced by Japan's 2022 health policy did not result in a reduction in overall drug costs, biosimilar use in oncology significantly increased.

Financial Incentives Boost Oncology Biosimilar Adoption, but Costs Remain Unchanged 

About

Editorial

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

Understanding and Improving Access of Biosimilars in Oncology

Biosimilars in Oncology: Addressing Awareness

Current State of Biosimilars: Approval, Availability, and Efficacy

Biosimilars in Oncology: Equivalency and Cost

Are Biosimilar Costs a Factor for Patients?

Biosimilars: Addressing Roadblocks to Market Adoption

Switching to Available Biosimilars in Oncology

Determining Biosimilars' Role in the Formulary

Market-Access Considerations for Biosimilars in Oncology

Where Do Biosimilars Fit in to the Treatment Landscape?

Multiple Biosimilars for a Single-Reference Biologic  

Strategies for Incorporating Biosimilars Into Care Plans

Incorporating Biosimilars in Oncology: Working Collaboratively

Economic Impact of Biosimilars in Oncology

Biosimilars in Oncology: Long-Term Financial Benefit

Competition in the Biosimilar Marketplace

Biosimilars in Oncology: Future Directions